Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

THE DOSING STORY:

ONE FDA-approved treatment, ONE small* capsule, ONE daily dose1

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule
NUPLAZID® (pimavanserin) 34mg Bottle Image

Confidently prescribe NUPLAZID® (pimavanserin) 34 mg, single once-daily capsule, for appropriate patients at the first sign of Parkinson’s disease (PD)-related delusions and hallucinations.1

*Actual size is 14.3 mm x 5.3 mm.

FDA Approved

ONE FDA-approved treatment1

  • The only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients without impacting motor function
    • In the 6-week studies, 80% of patients were aged 65 years or older*
Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)

ONE small capsule

  • 34 mg now in one single capsule
One Daily Dose

ONE daily dose

  • Taken orally with or without food
  • No dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID
  • Avoid the use of NUPLAZID in combination with other drugs known to prolong the QT interval
  • For patients taking strong or moderate CYP3A4 inducers, avoid combination use with NUPLAZID

*In the clinical studies, the maximum age of patients on NUPLAZID was 85 years old vs 90 years old for placebo.2
Actual size is 14.3 mm x 5.3 mm.

The full therapeutic-level steady-state plasma concentration of NUPLAZID 34 mg was reached in ~12 days with continuous treatment, without titration.1,2

Simulation of a Typical Concentration Profile of Once-daily NUPLAZID® (pimavanserin) 34 mg, Graph
  • Half-life (t1/2) is 57 hours1

Dosing and administration considerations1

  • For patients taking a strong CYP3A4 inhibitor, reduce the dosage of NUPLAZID to 10 mg daily
  • For patients taking strong or moderate CYP3A4 inducers, avoid combination use with NUPLAZID
  • Avoid the use of NUPLAZID in patients with known QT prolongation or in combination with other drugs known to prolong QT interval
  • NUPLAZID does not require a dosage adjustment in elderly patients, in patients with mild to severe renal impairment or end-stage renal disease (ESRD), or in patients with hepatic impairment*

*Increased exposure (Cmax and AUC) to NUPLAZID occurred in patients with severe renal impairment (CrCl>30 mL/min, Cockcroft-Gault) in a renal impairment study. NUPLAZID should be used with caution in patients with severe renal impairment and ESRD.

NUPLAZIDconnect™ Logo

NUPLAZIDconnect™ makes it easy to get patients started on treatment.

For healthcare professionals